The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess evidence and make recommendations, which were subject to public comment. Results: The panel agreed on 25 recommendations and 2 good practice statements to optimize management of patients receiving anticoagulants. Conclusions: Strong recommendations included using patient self-management of international normalized ratio (INR) with home point-of-care INR monitoring for vitamin K antagonist therapy and against using periprocedural low-molecular-weight heparin (LMWH) bridging therapy. Conditional recommendations included basing treatment dosing of LMWH on actual body weight, not using anti factor Xa monitoring to guide LMWH dosing, using specialized anticoagulation management services, and resuming anticoagulation after episodes of life-threatening bleeding. Summary of recommendations Anticoagulant therapy is complex and associated with both substantial benefits (reduced risk for thrombus extension and fatal pulmonary embolism [PE] in the setting of acute illness and recurrent venous thromboembolism [VTE] thereafter) and risks (life-threatening bleeding complications).1 Recognizing and mitigating risk for harm from anticoagulants requires an evidence-based approach to anticoagulant management and patient education. These guidelines focus on the optimal management of anticoagulant drugs for the prevention and treatment of VTE following the choice of an anticoagulant. Key management strategies for optimal use of anticoagulants include initial anticoagulant dose selection bloodadvances.2018024893. Resources for implementing these guidelines, including apps, patient decision aids, and teaching slide sets, may be accessed at the ASH web page hematology.org/vte. The full-text version of this article contains a data supplement. 